ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / POCI
ECOR (29) OM (34) HYPR (38) QTI (29) ⌘ Pro Terminal β†’

Precision Optics Corporation Inc. (POCI) β€” RQD Stock Rating Cockpit

$4.80 +3.23% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.82

Precision Optics Corporation Inc. (POCI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $51.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on POCI Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is POCI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Precision Optics Corporation Inc. (NASDAQ: POCI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $4.80 (+3.23% 1D, market cap $51.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, POCI ranks #767 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does POCI compare to ECOR and OM in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), POCI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 17.8%, and ROIC of -35.0%. By comparison, ECOR (electroCore Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M) and OM (Outset Medical Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M). Among the 5-stock peer group, POCI leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for POCI?
β–Ό

Per POCI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000867840), Precision Optics Corporation Inc. generated $19.1M in revenue (-0.1% YoY), -$5.8M in net income, and -$3.6M in free cash flow against $22.9M in total assets and $1.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.82 (+0.39%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (5)Whales (10)SEC (3)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$6 Bull$4 Base$3 Bear
πŸ“¬ FREE POCI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for POCI)Realized 20D OHLCV Swing Band: Β±8.3%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY POCI SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+11/20 pts (35% of score)

FRED Regime Γ— Technicals: 48% of 52W Range β€’ RSI-14 at 59.5 (BULLISH MOMENTUM)

β–² #2 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (Β±8.3% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
23
Grade E$4.56-6.6% Next Q
Q2 (-2Q)
26
Grade E$4.26+3.5% Next Q
Q3 (-1Q)
28
Grade E$4.41+8.8% Next Q
Current
31
Grade E$4.80-9.4% Hist 90D Ξ±
Trajectory: E (23) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a POCI Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While POCI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.42) and Max Pain ($5.04) forces dealer call-delta covering toward $6.46.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $POCIβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPOCI Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
59.530 Oversold Β· 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE48% OF RANGE
L: $4$4.80H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on POCI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 17.8% gross margin and -7.18% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (18)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

13/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like POCI
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring POCI)

  • βœ“Walkthrough of POCI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
POCI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.48%β–² RESISTANCE BREAKOUT
2026-11-03O $4.59H $4.80L $4.59C $4.80VOL 11.3K
RES: $4.66SUP: $4.01SMA50: $4.42SMA200: $4.63
$6.30$5.69$5.07$4.46$3.85RES $4.66SUP $4.01$4.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

POCI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ POCI Butterfly Map β†’ + Track POCI β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on POCI today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for POCI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for POCI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (POCI)

Health Care Rank #767 of 1015 βš”οΈ ECOR vs POCI Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (POCI vs. ECOR, OM, HYPR, QTI)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Precision Optics Corporation Inc. (POCI) ranks #767 by composite RQD confidence (31/100, grade E) and #742 by equity capitalization ($51.1M). Within this direct 5-issuer industry benchmark cohort, POCI leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with POCI at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
POCI ACTIVE
Precision Optics Corporation Inc.
E 31/100 β€” 17.8% -35.0% +3.23% $51.1M Benchmark Subject
ECOR
electroCore Inc.
E 29/100 β€” 86.8% -35.0% -4.79% $67.8M /ecor-vs-poci β†’
OM
Outset Medical Inc.
E 34/100 β€” 39.1% -28.0% -0.25% $75.8M /om-vs-poci β†’
HYPR
Hyperfine Inc. (Class A)
D- 38/100 β€” 49.8% -35.0% +0.99% $76.1M /hypr-vs-poci β†’
QTI
QT Imaging Holdings Inc.
E 29/100 β€” 45.4% -35.0% +0.47% $31.3M /qti-vs-poci β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-06-30 β€’ CIK 0000867840 β†—

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Precision Optics Corporation Inc. (POCI) reported GAAP revenue of $19.1M (-0.1% vs. FY2024 revenue of $19.1M , and -9.3% cumulative change since FY2023) , GAAP net income of -$5.8M, operating cash flow of -$3.4M, and free cash flow of -$3.6M (-22.6% YoY). On the balance sheet, POCI closed FY2025 with $22.9M in total assets against $1.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $19.1M -$5.8M -$3.4M -$3.6M $22.9M $1.0M
FY2024 (FY) 2024-06-30 $19.1M -$3.0M -$2.7M -$3.0M $17.5M $1.6M
FY2023 (FY) 2023-06-30 $21.0M -$144.6K -$81.1K -$81.1K β€” β€”

3. POCI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is POCI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Precision Optics Corporation Inc. (NASDAQ: POCI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $4.80 (+3.23% 1D, market cap $51.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, POCI ranks #767 in composite RQD confidence.

How does POCI compare to ECOR and OM in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), POCI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 17.8%, and ROIC of -35.0%. By comparison, ECOR (electroCore Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M) and OM (Outset Medical Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M). Among the 5-stock peer group, POCI leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for POCI?

Per POCI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000867840), Precision Optics Corporation Inc. generated $19.1M in revenue (-0.1% YoY), -$5.8M in net income, and -$3.6M in free cash flow against $22.9M in total assets and $1.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is POCI trading relative to its 50-day, 200-day, and 52-week technical levels?

POCI last traded at $4.80 (+3.23% on volume of 31,437 shares), positioning the stock +8.60% above its 50-day simple moving average ($4.42) and +3.67% above its 200-day simple moving average ($4.63). Across its 52-week range of $3.55 to $6.15, POCI sits at the 48.1% percentile with a 14-day RSI of 59.5 (BULLISH MOMENTUM) and an implied next-earnings move of Β±8.3% ($4.40 to $5.20).

Direct Sub-Reports: POCI RQD Cockpit POCI 12M Forecast POCI Earnings & Move POCI Dividends & DRIP POCI Insiders & 13F POCI Whale Options POCI Profit Sankey POCI News & Why
ROARABLE RATING BRIEF β€’ RQD 31/100 (E) βœ“ SEC XBRL & RQD VERIFIED

POCI β€” Precision Optics Corporation Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Precision Optics Corporation Inc. (POCI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.80 (+3.23% 1D, market capitalization $51.1M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 17.8%, operating margin of -29.1%, and free cash flow yield of -7.18%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of 0.11x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Precision Optics Corporation Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The profile lists market capitalization as $0.1B, which is consistent with the $50.5M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Precision Optics Corporation Inc. (POCI) reported $19.1M in annual revenue (up from $19.1M in FY2024, -0.1% YoY) and -$5.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($21.0M revenue, -$144.6K net income) through FY2025, POCI scaled operating cash flow to -$3.4M and free cash flow to -$3.6M, backed by $22.9M in total assets against $1.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.18% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $3.55 – $6.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -29.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. Sector correlations and 2nd-order bottlenecks are β€” Investors should note that the absence of mapped links means no ripple effects can be traced from the source data.

  • Key Question #1: Can POCI sustain or expand its -29.1% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.1M and free cash flow of -$3.6M, how will capital allocation balance growth reinvestment against $1.0M in total debt?
  • Key Question #3: How sensitive is POCI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

POCI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Precision Optics Corporation Inc. (POCI) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to POCI Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

POCI Bull vs. Bear Conversation Board β€” What's Your Call at $4.80?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON POCI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on POCI:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $5.39 (+15.9%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 10/20 in the RQD rating, the strongest pillar, suggesting some market support

Picked up a starter position in POCI in my $100K Virtual Cash book at $4.65. Institutional accumulation and options positioning score 10/20 in the RQD rating, the strongest pillar, suggesting some market support despite weak fundamentals.. Trading inside a $3.55–$6.15 52-week range with -7.18% FCF yield gives solid downside support if Biotechnology: Electromedical & Electrotherapeutic Apparatus multiples expand this quarter.

ArenaChamp_24 πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (17.8%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.00 (-14.0%)
Spot @ $4.65

A 0.2 Altman Z-Score, 3/9 Piotroski F-Score, -35% ROIC, and -7.18% FCF yield together signal forensic balance-sheet and cash-generation

A 0.2 Altman Z-Score, 3/9 Piotroski F-Score, -35% ROIC, and -7.18% FCF yield together signal forensic balance-sheet and cash-generation stress.. Look at the math on POCI: paying current EV/EBITDA multiples for -35.0% ROIC and -29.1% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $4.09 before getting long.

LIVE TAPE